Home
DNLI
DNLI News

Latest Denali Therapeutics Inc. (DNLI) News on November 17, 2024

We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely

Simply Wall St.

2 days ago

We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely

MT Newswires

4 days ago

Denali Therapeutics Insider Sold Shares Worth $1,932,665, According to a Recent SEC Filing

Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging

Zacks

9 days ago

Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

GlobeNewswire

11 days ago

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for

Zacks

18 days ago

Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for

Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Zacks

19 days ago

Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

MT Newswires

a month ago

Denali Therapeutics Insider Sold Shares Worth $1,107,600, According to a Recent SEC Filing

Denali Therapeutics Inc. (DNLI): Jeff Bezos Is Buying This Stock Now

Insider Monkey

a month ago

Denali Therapeutics Inc. (DNLI): Jeff Bezos Is Buying This Stock Now

Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength?

Zacks

a month ago

Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength?

MT Newswires

2 months ago

UBS Adjusts Denali Therapeutics Price Target to $46 From $32, Maintains Buy Rating

Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?

Zacks

2 months ago

Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?

Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?

Zacks

2 months ago

Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?

Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?

Zacks

2 months ago

Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?

Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug

Zacks

2 months ago

Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug

Why Is BioMarin (BMRN) Up 5.4% Since Last Earnings Report?

Zacks

2 months ago

Why Is BioMarin (BMRN) Up 5.4% Since Last Earnings Report?

High-dose Spinraza meets study goal; Top Dyne executives exit

BioPharma Dive

2 months ago

High-dose Spinraza meets study goal; Top Dyne executives exit

MT Newswires

2 months ago

Wedbush Adjusts Price Target on Denali Therapeutics to $27 From $26, Maintains Outperform Rating

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

GlobeNewswire

2 months ago

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

Denali Therapeutics (NASDAQ:DNLI) shareholders are up 3.4% this past week, but still in the red over the last three years

Simply Wall St.

3 months ago

Denali Therapeutics (NASDAQ:DNLI) shareholders are up 3.4% this past week, but still in the red over the last three years

MT Newswires

3 months ago

Denali Therapeutics Insider Sold Shares Worth $549,928, According to a Recent SEC Filing

Genetic testing in Parkinson’s disease patients: a standard of care imperative?

Medical Device Network

3 months ago

Genetic testing in Parkinson’s disease patients: a standard of care imperative?

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

GlobeNewswire

3 months ago

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade

Zacks

3 months ago

Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade

MT Newswires

3 months ago

B. Riley Adjusts Price Target on Denali Therapeutics to $33 From $36, Maintain Buy Rating

MT Newswires

3 months ago

Wedbush Adjusts Denali Therapeutics' PT to $26 From $30, Keeps Outperform Rating

MT Newswires

4 months ago

Denali Therapeutics Shares Fall After Swing to Q2 Net Loss

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire

4 months ago

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?

Zacks

4 months ago

Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?

Denali Therapeutics Stock Gets Technical Rating Upgrade

Investor's Business Daily

4 months ago

Denali Therapeutics Stock Gets Technical Rating Upgrade

Denali (DNLI) Outperforms Industry in 3 Months: Here's Why

Zacks

5 months ago

Denali (DNLI) Outperforms Industry in 3 Months: Here's Why

Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?

Zacks

5 months ago

Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?

Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?

Zacks

5 months ago

Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Simply Wall St.

5 months ago

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?

Zacks

5 months ago

Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?

Denali's (DNLI) Candidate Selected for FDA's START Pilot Program

Zacks

5 months ago

Denali's (DNLI) Candidate Selected for FDA's START Pilot Program

MT Newswires

5 months ago

Denali Therapeutics' Enzyme Replacement Therapy Picked for FDA's START Pilot Program; Shares Rise

Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

GlobeNewswire

5 months ago

Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

The Consensus EPS Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Just Fell Dramatically

Simply Wall St.

6 months ago

The Consensus EPS Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Just Fell Dramatically

Denali Therapeutics First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023)

Simply Wall St.

6 months ago

Denali Therapeutics First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023)

MT Newswires

6 months ago

Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating

MT Newswires

6 months ago

Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating

Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus

Zacks

6 months ago

Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus

GuruFocus.com

6 months ago

Denali Therapeutics Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic Shifts

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire

6 months ago

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

GlobeNewswire

7 months ago

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Is There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 50% Undervaluation?

Simply Wall St.

7 months ago

Is There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 50% Undervaluation?

Why Denali Therapeutics (DNLI) Stock Might be a Great Pick

Zacks

7 months ago

Why Denali Therapeutics (DNLI) Stock Might be a Great Pick

Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?

Zacks

8 months ago

Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?

Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?

Zacks

8 months ago

Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?

Further weakness as Denali Therapeutics (NASDAQ:DNLI) drops 7.4% this week, taking three-year losses to 67%

Simply Wall St.

8 months ago

Further weakness as Denali Therapeutics (NASDAQ:DNLI) drops 7.4% this week, taking three-year losses to 67%

Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up

Zacks

9 months ago

Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up

Denali Therapeutics Inc (DNLI) Reports Full Year and Q4 2023 Financial Results

GuruFocus.com

9 months ago

Denali Therapeutics Inc (DNLI) Reports Full Year and Q4 2023 Financial Results

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

GlobeNewswire

9 months ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Denali Therapeutics Announces $500 million Private Placement Equity Financing

GlobeNewswire

9 months ago

Denali Therapeutics Announces $500 million Private Placement Equity Financing

Denali, fresh off study setback, gets $500M lift

BioPharma Dive

9 months ago

Denali, fresh off study setback, gets $500M lift

Reuters

9 months ago

UPDATE 2-Denali-Sanofi's ALS drug fails to meet mid-stage trial goal

Reuters

9 months ago

Denali-Sanofi's ALS drug fails to meet main goal of mid-stage trial

ALS drug from Denali, Sanofi falls short in mid-stage study

BioPharma Dive

9 months ago

ALS drug from Denali, Sanofi falls short in mid-stage study

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

GlobeNewswire

9 months ago

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

Is Coursera, Inc. (NYSE:COUR) Potentially Undervalued?

Simply Wall St.

9 months ago

Is Coursera, Inc. (NYSE:COUR) Potentially Undervalued?

Coursera, Inc. (NYSE:COUR) Q4 2023 Earnings Call Transcript

Insider Monkey

9 months ago

Coursera, Inc. (NYSE:COUR) Q4 2023 Earnings Call Transcript

Newell Brands (NWL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks

9 months ago

Newell Brands (NWL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Why Federated Hermes (FHI) is a Top Momentum Stock for the Long-Term

Zacks

9 months ago

Why Federated Hermes (FHI) is a Top Momentum Stock for the Long-Term

Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™

GlobeNewswire

10 months ago

Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™

Baillie Gifford Reduces Stake in Denali Therapeutics Inc

GuruFocus.com

10 months ago

Baillie Gifford Reduces Stake in Denali Therapeutics Inc

Black Stone Minerals, L.P. Maintains Fourth Quarter Distribution for Common Units and Schedules Earnings Call to Discuss Fourth Quarter and Year-End 2023 Results

Business Wire

10 months ago

Black Stone Minerals, L.P. Maintains Fourth Quarter Distribution for Common Units and Schedules Earnings Call to Discuss Fourth Quarter and Year-End 2023 Results

Visteon to Announce Fourth Quarter and Full-Year 2023 Results on Feb. 20

GlobeNewswire

10 months ago

Visteon to Announce Fourth Quarter and Full-Year 2023 Results on Feb. 20

Tri Pointe Homes Named to 2024 List of Fortune World’s Most Admired Companies™

GlobeNewswire

10 months ago

Tri Pointe Homes Named to 2024 List of Fortune World’s Most Admired Companies™

4 Apparel Stocks That Look Well-Poised for Success in 2024

Zacks

10 months ago

4 Apparel Stocks That Look Well-Poised for Success in 2024

The Zacks Analyst Blog Highlights American Eagle Outfitters, Deckers Outdoor, Abercrombie & Fitch and The Gap

Zacks

10 months ago

The Zacks Analyst Blog Highlights American Eagle Outfitters, Deckers Outdoor, Abercrombie & Fitch and The Gap

Kraft Heinz's (KHC) Pricing & Transformation Efforts Solid

Zacks

10 months ago

Kraft Heinz's (KHC) Pricing & Transformation Efforts Solid

Denali's (DNLI) Pipeline Progresses Despite Stiff Competition

Zacks

10 months ago

Denali's (DNLI) Pipeline Progresses Despite Stiff Competition

Boston Beer and Huntsman have been highlighted as Zacks Bull and Bear of the Day

Zacks

10 months ago

Boston Beer and Huntsman have been highlighted as Zacks Bull and Bear of the Day

Valley National Bancorp Full Year 2023 Earnings: EPS Misses Expectations

Simply Wall St.

10 months ago

Valley National Bancorp Full Year 2023 Earnings: EPS Misses Expectations

Summit Materials Announces Fourth Quarter and Full Year 2023 Results Conference Call Date

PR Newswire

10 months ago

Summit Materials Announces Fourth Quarter and Full Year 2023 Results Conference Call Date

GATX Corporation (NYSE:GATX) Q4 2023 Earnings Call Transcript

Insider Monkey

10 months ago

GATX Corporation (NYSE:GATX) Q4 2023 Earnings Call Transcript

Sabra Health Care REIT, Inc. Announces Tax Treatment of 2023 Distributions

Business Wire

10 months ago

Sabra Health Care REIT, Inc. Announces Tax Treatment of 2023 Distributions

5 Promising Price-to-Book Value Stocks to Buy Now

Zacks

10 months ago

5 Promising Price-to-Book Value Stocks to Buy Now

Estimating The Intrinsic Value Of Southwest Gas Holdings, Inc. (NYSE:SWX)

Simply Wall St.

10 months ago

Estimating The Intrinsic Value Of Southwest Gas Holdings, Inc. (NYSE:SWX)

Strength Seen in Impinj (PI): Can Its 11.4% Jump Turn into More Strength?

Zacks

10 months ago

Strength Seen in Impinj (PI): Can Its 11.4% Jump Turn into More Strength?

Vistia Health selects Progyny as its preferred fertility and family building benefits provider

PR Newswire

10 months ago

Vistia Health selects Progyny as its preferred fertility and family building benefits provider

White Mountains Insurance Group, Ltd. (NYSE:WTM) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Simply Wall St.

10 months ago

White Mountains Insurance Group, Ltd. (NYSE:WTM) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Optimistic Outlook for Offshore Drilling as E&P Capex Surge

Zacks

10 months ago

Optimistic Outlook for Offshore Drilling as E&P Capex Surge

3 Mid-Cap Stocks Poised for a Breakout in 2024

InvestorPlace

10 months ago

3 Mid-Cap Stocks Poised for a Breakout in 2024

Box Sign Achieves Support for FDA 21 CFR Part 11 Compliance to Streamline Regulated E-signature Workflows

Business Wire

10 months ago

Box Sign Achieves Support for FDA 21 CFR Part 11 Compliance to Streamline Regulated E-signature Workflows

2024 HARLEY-DAVIDSON® HOMECOMING™ FESTIVAL TO FEATURE HEADLINING ACTS RED HOT CHILI PEPPERS, JELLY ROLL AND HARDY

PR Newswire

10 months ago

2024 HARLEY-DAVIDSON® HOMECOMING™ FESTIVAL TO FEATURE HEADLINING ACTS RED HOT CHILI PEPPERS, JELLY ROLL AND HARDY

BURFORD CAPITAL ANNOUNCES PRIVATE OFFERING OF SENIOR NOTES

PR Newswire

10 months ago

BURFORD CAPITAL ANNOUNCES PRIVATE OFFERING OF SENIOR NOTES

Pilgrim's Pride (PPC) Gains on Pricing, Operational Efficiency

Zacks

10 months ago

Pilgrim's Pride (PPC) Gains on Pricing, Operational Efficiency

Better Than BTC: 7 Crypto Stocks With the Potential to Outperform Bitcoin

InvestorPlace

10 months ago

Better Than BTC: 7 Crypto Stocks With the Potential to Outperform Bitcoin

Fade to Black: 3 Coal Stocks to Offload as the Industry Shifts

InvestorPlace

10 months ago

Fade to Black: 3 Coal Stocks to Offload as the Industry Shifts

Agree Realty Declares Monthly Common and Preferred Dividends

PR Newswire

10 months ago

Agree Realty Declares Monthly Common and Preferred Dividends

40 Cities with the Lowest Life Expectancy in the US

Insider Monkey

10 months ago

40 Cities with the Lowest Life Expectancy in the US

Dippin' Dots Now Available at Peter Piper Pizza Locations in Arizona

PR Newswire

10 months ago

Dippin' Dots Now Available at Peter Piper Pizza Locations in Arizona

Adient to discuss Q1 fiscal 2024 financial results on February 7, 2024

PR Newswire

10 months ago

Adient to discuss Q1 fiscal 2024 financial results on February 7, 2024

CONSOL Energy Schedules Fourth Quarter 2023 Earnings Release and Conference Call

PR Newswire

10 months ago

CONSOL Energy Schedules Fourth Quarter 2023 Earnings Release and Conference Call

2024's Rough Start: More Than A Half Dozen REITs Get Downgrades

Benzinga

10 months ago

2024's Rough Start: More Than A Half Dozen REITs Get Downgrades

Next-Gen Wealth: 7 Stocks to Catapult You to Millionaire Status

InvestorPlace

10 months ago

Next-Gen Wealth: 7 Stocks to Catapult You to Millionaire Status

Prediction: These Could Be the Best-Performing Fintech Stocks Through 2030

Motley Fool

10 months ago

Prediction: These Could Be the Best-Performing Fintech Stocks Through 2030

Brady Corp's Dividend Analysis

GuruFocus.com

10 months ago

Brady Corp's Dividend Analysis

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

GlobeNewswire

10 months ago

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Share on Social Networks: